Keara Kennedy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Keara Kennedy has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Allison Thibodeau
Fred Hutchinson Cancer Center
1 shared publication - Catherine Liu
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
1 shared publication - Elizabeth M. Krantz
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
1 shared publication - Emily A. Rosen
Fred Hutchinson Cancer Center
1 shared publication - Frank Tverdek
Department of Pharmacy, Fred Hutchinson Cancer Center , Seattle, Washington
1 shared publication - Jason P. Cooper
Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, USA
1 shared publication
Latest Publications
- 21 June 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (10) , 1422-1431.e4
Serum Interleukin-6 Levels in Endometriosis and Endometriosis-Associated Ovarian Cancer: A Systematic Review and Meta-Analysis Demonstrating a Biological Gradient
- 21 June 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (10) , 1422-1431.e4
Serum Interleukin-6 Levels in Endometriosis and Endometriosis-Associated Ovarian Cancer: A Systematic Review and Meta-Analysis Demonstrating a Biological Gradient
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Open AccessDiagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.